69 completed, 19 terminated, 8 active not recruiting, 6 unknown. 64 Phase 2, 29 Phase 1, 18 Not applicable, 5 Early Phase 1, 2 Phase 3.
Follow Stage IV Prostate Cancer: new trials by email Literature Review of Stage IV Prostate Cancer trials Research Report on Stage IV Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel - Prostate Cancer, Stage IV Prostate Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2022-01-25 | 2025-12-04 |
| Ask Questions (ASQ):Implementation of a Communication Intervention Behavioral Intervention - Stage II Breast Cancer, Stage III Breast Cancer | Not applicable | Completed | Barbara Ann Karmanos Cancer Institute | 81 | 2021-08-25 | 2023-08-16 |
| Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites Canady Helios Cold Plasma Scalpel - Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer | Not applicable | Unknown | Jerome Canady, M.D. | 20 | 2019-07-30 | 2021-08-09 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer Dietary Intervention, Educational Intervention, Exercise Intervention - Cancer Survivor, Obesity | Not applicable | Recruiting | Roswell Park Cancer Institute | 50 | 2019-05-02 | 2026-05-07 |
| Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma | Phase 2 | Terminated | University of Utah | 1 | 2019-02-08 | 2020-06-25 |
| Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), Radical Prostatectomy - Stage III Prostate Cancer, Stage IIIA Prostate Cancer | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-12-24 | 2025-04-29 | |
| Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Enzalutamide, Laboratory Biomarker Analysis, Radium Ra 223 Dichloride - Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone | Phase 2 | Active not recruiting | University of Southern California | 30 | 2018-11-21 | 2026-06-03 |
| Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone | Phase 2 | Completed | University of Utah | 17 | 2018-10-02 | 2024-11-29 |
| Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer Dibenzyl trisulphide capsules, Stage IV Breast Cancer Placebo, Stage IV: Colon Cancer Placebo - Stage IV Prostate Cancer, Stage IV Colon Cancer | Early Phase 1 | Unknown | The University of The West Indies | 104 | 2018-10-01 | 2019-10-08 |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone - Prostate Cancer, Stage IV Prostate Cancer | Early Phase 1 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2018-09-17 | 2025-12-04 |
| Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy Image Guided Biopsy - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Not applicable | Withdrawn | Jonsson Comprehensive Cancer Center | 2018-06-14 | 2020-07-23 | |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2018-01-30 | 2023-05-01 |
| Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration - Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm | Not applicable | Completed | Rutgers, The State University of New Jersey | 14 | 2017-12-06 | 2021-04-08 |
| Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer GnRH agonist/antagonist, Prednisone, Abiraterone Acetate - Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma | Phase 4 | Active not recruiting | Northwestern University | 100 | 2017-03-31 | 2026-02-24 |
| Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Enzalutamide, Indomethacin - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Mamta Parikh | 38 | 2017-01-17 | 2023-11-29 |
| Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Olaparib, Abiraterone Acetate, Prednisone - Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair | Phase 2 | Active not recruiting | Northwestern University | 70 | 2017-01-12 | 2026-06-01 |
| Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer Enzalutamide, Niclosamide - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 1 | Completed | University of California, Davis | 6 | 2017-01-09 | 2026-05-06 |
| Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies Carboplatin, Docetaxel - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Terminated | Seattle Institute for Biomedical and Clinical Research | 2 | 2016-11-01 | 2021-08-05 |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Abiraterone Acetate, Niclosamide, Prednisone - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Active not recruiting | Mamta Parikh | 37 | 2016-10-01 | 2024-12-18 |
Showing 20 of 109. Sign in to see all of them.
Prostatic Neoplasms (109) · Breast Neoplasms (12) · Uterine Cervical Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Renal Cell (6) · Colonic Neoplasms (6) · Urinary Bladder Neoplasms (6) · Breast Neoplasms, Male (5) · Carcinoma, Ovarian Epithelial (5) · Stomach Neoplasms (5) · Carcinoma, Hepatocellular (4) · Colorectal Neoplasms (4) · Endometrial Neoplasms (4) · Esophageal Neoplasms (4) · Lung Neoplasms (4)
Genital Diseases (109) · Genital Diseases, Male (109) · Genital Neoplasms, Male (109) · Male Urogenital Diseases (109) · Neoplasms by Site (109) · Prostatic Diseases (109) · Urogenital Diseases (109) · Urogenital Neoplasms (109) · Neoplasms (107) · Breast Diseases (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases, Female (11)
Prednisone (17) · Docetaxel (14) · enzalutamide (12) · Abiraterone Acetate (10) · Leuprolide (9) · bicalutamide (8) · Goserelin (7) · Magnetic Resonance Spectroscopy (7) · Gonadotropin-Releasing Hormone (4) · Sirolimus (4) · abiraterone (4) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (4) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (3) · CTLA-4 Antigen (3) · Diet Therapy (3)
National Cancer Institute (NCI) (33) · Roswell Park Cancer Institute (6) · University of Southern California (6) · Barbara Ann Karmanos Cancer Institute (5) · University of Washington (5) · Mayo Clinic (4) · City of Hope Medical Center (3) · Jonsson Comprehensive Cancer Center (3) · OHSU Knight Cancer Institute (3) · Ohio State University Comprehensive Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · University of Chicago (3) · Burzynski Research Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
United States (102) · Canada (5) · China (1) · Jamaica (1) · Puerto Rico (1) · Singapore (1) · Switzerland (1)
Elisabeth Heath (3) · Evan Yu (3) · Russell Szmulewitz (3) · David Solit (2) · Jacek Pinski (2) · Maha Hussain (2) · Mamta Parikh (2) · Matthew Rettig (2) · Robert Montgomery (2) · Saby George (2) · Stanislaw R. Burzynski, MD, PhD (2) · Tomasz Beer (2) · Ulka Vaishampayan (2) · Adam Dicker, MD (1) · Agustin Garcia (1)
PMID 19349545, PMID 21106711, PMID 22932804, PMID 24048789, PMID 25199619, PMID 25847934, PMID 26450920, PMID 28178640, PMID 29476383, PMID 29590007, PMID 29684136, PMID 29876010, PMID 30682445, PMID 30700328, PMID 31611635, PMID 31838879, PMID 32850444, PMID 32974208, PMID 33270906, PMID 33496795, PMID 33885704, PMID 34028627, PMID 34616010, PMID 34845502, PMID 35277461, PMID 36358643, PMID 36898948, PMID 36996380, PMID 37509349, PMID 37922930, PMID 38992025, PMID 39076107, PMID 39663356, PMID 40132910, PMID 41346252, PMID 41378786
P30CA015704 (6), U01CA062491 (5), U10CA031946 (4), P30CA006973 (3), P30CA015083 (3), P30CA093373 (3), U01CA069856 (3), U10CA021115 (3), N01CM00071 (2), N01CM17101 (2), N01CM62201 (2), N01CM62202 (2), N01CM62206 (2), P30CA008748 (2), P30CA014089 (2)